These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 9400598)

  • 1. Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization.
    Zhang YJ; Fredriksson R; McKeating JA; Fenyö EM
    Virology; 1997 Nov; 238(2):254-64. PubMed ID: 9400598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
    Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid substitutions in the V3 loop are responsible for adaptation to growth in transformed T-cell lines of a primary human immunodeficiency virus type 1.
    Harrowe G; Cheng-Mayer C
    Virology; 1995 Jul; 210(2):490-4. PubMed ID: 7618285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.
    Pugach P; Kuhmann SE; Taylor J; Marozsan AJ; Snyder A; Ketas T; Wolinsky SM; Korber BT; Moore JP
    Virology; 2004 Mar; 321(1):8-22. PubMed ID: 15033560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the V2, V3, and CD4-binding domains of GP120 in curdlan sulfate neutralization sensitivity of HIV-1 during infection of T lymphocytes.
    Jagodzinski PP; Wustner J; Kmieciak D; Wasik TJ; Fertala A; Sieron AL; Takahashi M; Tsuji T; Mimura T; Fung MS; Gorny MK; Kloczewiak M; Kaneko Y; Kozbor D
    Virology; 1996 Dec; 226(2):217-27. PubMed ID: 8955041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.
    Louder MK; Sambor A; Chertova E; Hunte T; Barrett S; Ojong F; Sanders-Buell E; Zolla-Pazner S; McCutchan FE; Roser JD; Gabuzda D; Lifson JD; Mascola JR
    Virology; 2005 Sep; 339(2):226-38. PubMed ID: 16005039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates.
    Quakkelaar ED; Beaumont T; van Nuenen AC; van Alphen FP; Boeser-Nunnink BD; van 't Wout AB; Schuitemaker H
    Virology; 2007 Mar; 359(1):92-104. PubMed ID: 17052738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Back NK; Smit L; De Jong JJ; Keulen W; Schutten M; Goudsmit J; Tersmette M
    Virology; 1994 Mar; 199(2):431-8. PubMed ID: 8122371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
    Kang CY; Hariharan K; Posner MR; Nara P
    J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.
    Beaumont T; Quakkelaar E; van Nuenen A; Pantophlet R; Schuitemaker H
    J Virol; 2004 Jun; 78(11):5651-7. PubMed ID: 15140962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.
    Vella C; Zheng NN; Easterbrook P; Daniels RS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(13):933-46. PubMed ID: 12230936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.